TY - JOUR
T1 - Update Breast Cancer 2024 Part 3-Patients with Advanced Stage Breast Cancer
AU - Lüftner, Diana
AU - Kolberg, Hans Christian
AU - Hartkopf, Andreas D.
AU - Fehm, Tanja N.
AU - Welslau, Manfred
AU - Müller, Volkmar
AU - Schütz, Florian
AU - Fasching, Peter A.
AU - Jackisch, Christian
AU - Marme, Frederik
AU - Keller, Katharina
AU - Hörner, Manuel
AU - Goossens, Chloë
AU - Belleville, Erik
AU - Untch, Michael
AU - Thill, Marc
AU - Tesch, Hans
AU - Ditsch, Nina
AU - Radosa, Julia C.
AU - Banys-Paluchowski, Maggie
AU - Wöckel, Achim
AU - Harbeck, Nadia
AU - Stickeler, Elmar
AU - Bartsch, Rupert
AU - Aktas, Bahriye
AU - Schneeweiss, Andreas
AU - Ettl, Johannes
AU - Taran, Florin Andrei
AU - Janni, Wolfgang
AU - Würstlein, Rachel
AU - Lux, Michael P.
N1 - Publisher Copyright:
© 2025. The Author(s).
The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).
PY - 2025/5/15
Y1 - 2025/5/15
N2 - The use of CDK4/6 inhibitors, the new PI3K/AKT-kinase inhibitors, selective estrogen receptor-degraders (SERDs), antibody-drug conjugates, immune therapies and PARP inhibitors in recent years has resulted in a marked change in the therapy landscape for patients with advanced stage breast cancer. CDK4/6 inhibitors, trastuzumab deruxtecan, and sacituzumab govitecan have all been shown to provide significant overall survival benefits compared to conventional chemotherapy. Other substances are also showing promising results and hold out the hope that further analysis of the overall survival benefits will be available in the near future. The speed at which studies are now being carried out has markedly increased, and conferences and specialist journals are now constant sources of new information. This review summarizes the most recent publications and conference presentations on the treatment of patients with advanced stage breast cancer.
AB - The use of CDK4/6 inhibitors, the new PI3K/AKT-kinase inhibitors, selective estrogen receptor-degraders (SERDs), antibody-drug conjugates, immune therapies and PARP inhibitors in recent years has resulted in a marked change in the therapy landscape for patients with advanced stage breast cancer. CDK4/6 inhibitors, trastuzumab deruxtecan, and sacituzumab govitecan have all been shown to provide significant overall survival benefits compared to conventional chemotherapy. Other substances are also showing promising results and hold out the hope that further analysis of the overall survival benefits will be available in the near future. The speed at which studies are now being carried out has markedly increased, and conferences and specialist journals are now constant sources of new information. This review summarizes the most recent publications and conference presentations on the treatment of patients with advanced stage breast cancer.
UR - https://www.scopus.com/pages/publications/105005589317
UR - https://www.mendeley.com/catalogue/33a037d9-7a29-3372-91e1-ad830e78fe6a/
U2 - 10.1055/a-2515-2366
DO - 10.1055/a-2515-2366
M3 - Scientific review articles
C2 - 40386501
AN - SCOPUS:105005589317
SN - 0016-5751
VL - 85
SP - 507
EP - 519
JO - Geburtshilfe und Frauenheilkunde
JF - Geburtshilfe und Frauenheilkunde
IS - 5
ER -
